Cardiff Oncology Announced Initial Data From The CRDF-004 Phase 2 Trial Evaluating Onvansertib In Combination With Standard-of-care In Patients With First-Line RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology Announced Initial Data From The CRDF-004 Phase 2 Trial Evaluating Onvansertib In Combination With Standard-of-care In Patients With First-Line RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology宣佈了初始數據，來自於CRDF-004第2期試驗，評估Onvansertib與標準治療結合在首線RAS突變轉移性結直腸癌患者中的效果。
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm.
- In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30mg arm.
- Onvansertib was well tolerated at both doses.
- Additional clinical data from CRDF-004 trial expected in 1H 2025.
- 對RAS突變的轉移性結直腸癌進行的隨機二期CRDF-004臨床試驗的初步結果顯示，在30mg onvansertib劑量組中，ORR爲64%，而對照組的ORR爲33%。
- 在實驗組中，3000萬劑量的onvansertib顯示出比20mg劑量的onvansertib更高的ORR（64% vs. 50%），且在30mg組中腫瘤回歸更明顯。
- onvansertib在兩種劑量下均耐受良好。
- 預計在2025年上半年將推出CRDF-004試驗的附加臨床數據。
資訊熱榜
更新時間